The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS
Withdrawn before enrolling · Phase 3
Conditions studied: Pneumonia, Pneumocystis Carinii, HIV Infections
In brief
To determine the effect of methylprednisolone on respiratory failure in HIV-infected patients with presumed or confirmed pneumocystis carinii pneumonia who are stratified for presence or absence of respiratory failure at the time of randomization to the study.
Key facts
- Study ID
- NCT00000741
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 0
- Last updated by the study team
- 2021-11-04
Who can join
Age: 0 and older, up to 2. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Concurrent Medication:
- Allowed:
- Recombinant erythropoietin and any FDA-approved cytokine for management of anemia.
- Antiretroviral agents.
- Patients must have:
- Documented HIV infection.
- PCP.
- No more than 36 hours of prior primary therapy for confirmed or presumed PCP.
- Prior Medication:
- Allowed:
- Up to 35 hours of primary therapy for confirmed or presumed PCP.
You may not qualify if…
- Co-existing Condition:
- Patients with the following symptoms and conditions are excluded:
- Demonstrated intolerance to steroids.
- Requirement for steroids at greater than physiological doses for other medical conditions.
Where it is running
- UCSD Med Ctr / Pediatrics / Clinical Sciences — La Jolla, California, United States
- Chicago Children's Memorial Hosp — Chicago, Illinois, United States
- St Louis Univ School of Medicine — St Louis, Missouri, United States
- Bellevue Hosp / New York Univ Med Ctr — New York, New York, United States
- Columbia Presbyterian Med Ctr — New York, New York, United States
- Duke Univ Med Ctr — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.